Merck’s Breakthrough Cardiovascular Research to Take Center Stage at ACC.25

Merck, widely recognized for its commitment to cardiovascular innovation, is set to showcase groundbreaking research at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) in Chicago from March 29-31. The spotlight will be on the Phase 3 ZENITH trial, which evaluates WINREVAIR™ (sotatercept-csrk) for pulmonary arterial hypertension (PAH). The trial’s interim analysis revealed overwhelming efficacy, leading to an early study conclusion—a major milestone for PAH patients at high risk of mortality. Additionally, Merck will share real-world insights into cholesterol management, emphasizing barriers to achieving LDL-C goals and their impact on healthcare systems.

Merck’s participation at ACC.25 underscores its 60-year legacy in cardiovascular advancements, reinforcing its mission to improve patient outcomes through cutting-edge research. "Our goal is to provide meaningful insights that drive better disease management and patient care," said Dr. Eliav Barr, Merck’s Chief Medical Officer. Research presentations will include real-world data on cholesterol treatment patterns, a meta-analysis of residual cardiovascular risk, and a model evaluating the long-term impact of lipid-lowering therapies. By addressing gaps in cardiovascular care, Merck aims to shape the future of treatment strategies and help more patients achieve life-saving results.